Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,216.00    38.00 (1.74%)
Bid:
2,220.00
Ask:
2,228.00
Spread: 8.00 (0.36%)
Market Cap: £1.47b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

14 Sep 2017 17:30

RNS Number : 8203Q
Genus PLC
14 September 2017
 

14 September 2017

 

Genus plc

 

Director/PDMR Shareholding

 

Genus plc (LSE: GNS) announces that yesterday conditional nil-cost share options were granted under the Genus 2014 Performance Share Plan over ordinary shares in Genus to the Executive Directors and members of the Genus Executive Leadership Team ('GELT') as listed in table A below. In addition, following Genus's compulsory deferral requirements relating to the annual bonus earned by Executive Directors and GELT for the financial year ending 30 June 2017, nil-cost share options were granted over ordinary shares under Genus's Deferred Share Bonus Plan as listed in table B below.

Details of the performance conditions that apply to the nil-cost share options can be found in the Directors' Remuneration Report of the Genus 2017 Annual Report.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail of the nil-cost share option awards made on 13 September 2017.

 

For further information please contact:

 

Genus:

Cara Crichton, Deputy Company Secretary Tel: +44 (0)1256 347100

 

Table A - GELT 2014 Performance Share Plan Options

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Karim Bitar

2. Stephen Wilson

3. Bill Christianson

4. Nate Zwald

5. Jerry Thompson

6. Jonathan Lightner

7. Angelle Rosata

8. Dan Hartley

2.

Reason for the notification

a.

Position/status

1. Chief Executive

2. Group Finance Director

3. Chief Operating Officer Genus PIC

4. Chief Operating Officer Genus ABS Dairy

5. Chief Operating Officer Genus ABS Beef

6. Chief Scientific Officer & Head of Genus R&D

7. Group Human Resources Director

8. Group General Counsel & Company Secretary

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Genus plc

b.

LEI

54930022EOITNKSIGH56

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 10p each.

 

 

GB0002074580

b.

Nature of the transaction

Award of nil-cost share options granted under the Genus plc 2014 Performance Share plan over ordinary shares in Genus.

 

c.

Price(s) and volume(s)

Numbers 1 to 8 in the left hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

 

Price(s)

 

Volume(s)

1. 1,972.67p

56,404

2. 1,972.67p

38,221

3. 1,972.67p

22,278

4. 1,972.67p

18,661

5. 1,972.67p

18,661

6. 1,972.67p

22,278

7. 1,972.67p

17,800

8. 1,972.67p

19,009

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

 

e.

Date of the transaction

2017-09-13

f.

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

Table B - GELT Deferred Share Bonus Plan Options

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Karim Bitar

2. Stephen Wilson

3. Bill Christianson

4. Nate Zwald

5. Jerry Thompson

6. Jonathan Lightner

7. Dan Hartley

 

2.

Reason for the notification

a.

Position/status

1. Chief Executive

2. Group Finance Director

3. Chief Operating Officer Genus PIC

4. Chief Operating Officer Genus ABS Dairy

5. Chief Operating Officer Genus ABS Beef

6. Chief Scientific Officer & Head of Genus R&D

7. Group General Counsel & Company Secretary

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Genus plc

b.

LEI

54930022EOITNKSIGH56

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 10p each.

 

 

GB0002074580

b.

Nature of the transaction

Award of nil-cost share options granted under Genus's Deferred Share Bonus Plan following the compulsory deferral of 25% of annual bonus in respect of bonuses earned in the financial year ending 30 June 2017.

 

c.

Price(s) and volume(s)

Numbers 1 to 7 in the left hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.

 

Price(s)

 

Volume(s)

1. 1,972.67p

20,629

2. 1,972.67p

10,213

3. 1,972.67p

2,017

4. 1,972.67p

557

5. 1,972.67p

615

6. 1,972.67p

7,463

7. 1,972.67p

6,395

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

2017-09-13

f.

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUSUNRBKAKAAR
Date   Source Headline
16th Jun 20268:28 amRNSHolding(s) in Company
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.